BRIEF-Eiger Biopharmaceuticals updates on hypoglycemia study
December 12, 2016 at 08:17 AM EST
* Eiger biopharmaceuticals inc - clinical and regulatory advances in development of exendin 9-39 for treatment of post-bariatric hypoglycemia (pbh)
